Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
ABT 724 trihydrochloride (HB1883)
Description:Potent dopamine D4 receptor partial agonist
Purity:>99%
Amisulpride (HB1879)
Description:Potent, selective dopamine D2 and D3 receptor antagonist. Atypical antipsychotic.
Purity:>98%
Bromocriptine mesylate (HB1813)
Description:Potent, selective D2-like receptor agonist
Purity:>98%
Haloperidol hydrochloride (HB1842)
Description:Dopamine receptor antagonist with partial D2-like selectivity
Purity:>99%
Olanzapine (HB1786)
Description:5-HT2A and D2 antagonist. Potent DREADD agonist. Atypical antipsychotic.
Purity:>99%
Prochlorperazine dimaleate (HB1907)
Description:D2 receptor antagonist. Also 5-HT3 and nAChR antagonist.
Purity:>99%